Colossal Biosciences, an American biotechnology company, announced the "de-extinction" of the dire wolf, a prehistoric wolf species that died out more than 10,000 years ago, in April 2025. Three pups ...

More students are now using AI tools such as ChatGPT in class, raising urgent questions about cheating, innovation, and the future of education in the AI era.

How else could one explain the astonishing surge in foreign direct investment (FDI) filings in Romania in 2024?

Remember Florida’s “Don’t Say Gay” law? The unconstitutionally vague law imposed such unclear restrictions on teachers who speak about sexual orientation or gender identity that many feared they could ...

The Natural History Museum has been digitizing its collections for a number of years. Due to the size of its collections (25 million records representing 5.9 million specimens and rising), there are ...

The administration is pushing agencies to turn over information on where people work, study and live. The data is normally protected from dissemination.

For a long time now, we’ve known that social media – the access it opens up for young people and the power it can wield over their impressionable minds – is a double-edged sword ...

LOOK WHO’S BACK: Former President Joe Biden will address a conference in Chicago this evening with a speech on defending Social Security, per NBC Chicago. His intervention comes a little over a week ...

Gov. Josh Green has signed into law two bills regulating guns in the islands and is considering two others as the state Legislature this year moved to strengthen Hawaii’s already strict firearm laws.

Greenwald and Taibbi arrived at their journalistic celebrity through different paths. Greenwald, a civil libertarian and (usually) strident critic of U.S. military and intelligence policy, cut his ...

Catch all the key moments from Free Practice 2 at the Miami E-Prix, Round 5 of Formula E Season 11. The drivers hit the track to fine-tune their strategies, test car setups, and push the limits before ...

Jonathan Kimmelman, PhD, has published multiple research papers and gotten into an inordinate number of debates about the clinical value of phase 1 trials.“I’ve argued for a long time that for phase 1 ...